Management Team and Board of Directors

George Skouteris, MD, D.Phil., FRCPath., CEO & CSO (acting)

Qualified in Medicine, in GMC’s (UK) specialist’s register. Doctor of Philosophy in Biochemistry & Molecular Biology (D.Phil., University of Oxford, 1988). He has served in various positions within the Academia such as Group Leader at the Department of Pathology, Duke University Medical Center, NC, US as senior Investigator at the German Cancer Research Centre (DKFZ, Heidelberg) & senior Lecturer, University College London, UK) for a total of ~20 years.
Since 2002 he has continued in various R&D and medical director positions in Pharmaceutical companies to include Eli Lilly (Oncology), Roche Products Ltd. (Oncology & Hepatitis), Daiichi Sankyo Inc. (Neuropathic Pain) and GSK (Immunology & Oncology). He has co-authored about 40 peer-reviewed publications, edited 3 books, mostly in the signal transduction and receptor-ligand interactions arena and he is inventor in 3 patents.

Giuseppe Iuliano, Director

Qualified as an accountant who served in senior accountancy roles companies to include KPMG, Finalsa SA, Fiduciaire Corola, Fidacor SA, Dimension Data SA, Noble Resources, Stryker Osteonics SA and Alcon Pharmaceuticals.
He is experienced in corporate governance, day to day financial management as well as in strategic partnerships, budget projections, P/L accounting and extensive working knowledge of the Swiss and international accountancy standards.

Domenico Merante MD, Chief Medical Officer (CMO)

Result-driven and excellence-focused physician with 21 years international experience in the pharmaceutical industry in clinical development and medical affairs. Nico comes in the company with robust history in clinical research with focus on neuroscience, pain, mostly type 2 diabetes associated with obesity, diabetic complications, metabolism, hypertension, metabolic syndrome and endocrinology. He is in the specialist’s register of the General Medical Council (UK) for Endocrinology & Diabetes. Serving in European and US managerial positions in medical departments to include head of Clinical positioning with Novo Nordisk (1999-2000, UK) and he continued as Senior Clinical Research Physician with Elli Lilly with focus the launching of an insulin analogue (Humalog) and leading the development of ruboxistaurin mesylate (an oral molecule investigated for the treatment of diabetic maculopathy and neuropathy) (2000-2004). He continued his clinical development career with GSK for 2 years (2004-2006) as medical director in Diabetes, Metabolism and Cardiovascular before moving to Daiichi Sankyo (UK) as senior medical director leading the Frontier Opportunities and Pain Division of the company at global level.
He was in charge of clinical development for Olmesartan (Hypertension) and later in charge for all the Pain programs of the company from late pre-clinical to Phase III, exploring voltage calcium gated channel ligands as well as Nav 1.7. sodium channel blocker (2006-2016). His latest role was Vice President for Shionogi HQ in London. He has co-authored more than 70 peer-reviewed publications and delivered numerous invited talks to meetings and conferences in Endocrinology, Pain and metabolism-related topics.

Dr Deepak Kotak (DK) MA(Oxon), MBBS, MRCP, FRCA, LL.Dip, LLM, Chief Business Officer (CBO)

Executive and business development roles in VIRxSYS, TraumaTec, BioElectronics and Protea Biosciences, start-up and early stage life science companies in the U.S. and EU. Negotiated research, development, licensing and distribution deals; involved in strategy, R&D and medical affairs. Fifteen years of medical experience including chronic pain and five years as a civil lawyer in London. Senior medial advisor to Ermgassen, a boutique investment bank.

Board of Directors

Dimitrios Goundis B.Sc (Hons), D.Phil. (Oxon), Non-Executive Director

Dimitri was educated in the U.K. with a degree in Chemistry and Biochemistry, and a Ph.D. in Molecular Biology (Immunology) from the University of Oxford. The Ph.D. work was done under the supervision of Rodney Porter, a Nobel laureate (1972).
He spent 2 years as a postdoctoral fellow at the Basel Institute for Immunology in Switzerland, and he then joined the Oncology Clinical Research group of Hoffmann La-Roche in Strasbourg, France. After 2 years in Clinical Research, he became Project Director, based in Basel, and was in charge of development projects in a number of therapeutic areas, incl. Metabolism, Cardiovascular and CNS.
He left Roche, in 1996, and spent 2 years in London, where he worked as a derivatives trader, and also attended the London Business School for a Certificate in Investment Management.
In 1998 he joined The Medicines Company (MDCO) in Basel, as Project Director. Following the listing (IPO) of MDCO on the NASDAQ (Aug 2000), he joined another start-up company in Basel, Speedel. He was the first full-time employee of Speedel, and played a key role in the development of the company for over 6 years, incl. its listing on the Zurich Stock Exchange (Sep 2005). He was promoted to Managing Director of Speedel Experimenta, a unit specializing in Chemistry/Lead Optimization and Pharmacology of new therapeutic agents. In September 2007 he became CEO at Acrongenomics, a start-up company active in the field of point-of-care diagnostics, based in Geneva.
Dimitri was asked to re-join The Medicines Company (MDCO) in Jan 2009. In Jan 2010 he became Global Head of Research and Development (R&D) of MDCO, and for that role he moved from Germany to the US (New Jersey). He re-engineered the R&D department, ca. 150 employees and annual budget of $120 mio, and met every single financial and development target set by the Board each year and each quarter. He was promoted to Senior Vice President of MDCO in 2011.
After 4 years in the US, he returned to Switzerland, and became Head of European Business Development for MDCO. He left MDCO in July 2015, after having spent 6 years with the company.
Dimitri has published over 20 scientific articles, including Nature and is co-inventor of a patent (both US & EU) on the potential therapeutic uses of the properdin and thrombospondin units.
Currently he is CEO of MaxiVax SA an Immuno-Oncology Biotechnology company with headquarters in Geneva.

Nick Rodgers BA FCA MSI, Non-Executive Director

Nick is an experienced chairman and non-executive director with a background as a succ essful corporate financier.
Significant exposure to c ompanies in the healthcare, medical, biotechnology, environmental and techno logy sectors. Nick has advised on or been involved with over 100 acquisition s or disposals, some 40 flotations and in excess of 20 takeovers. Nick start ed his strategic finance career with Ernst & Young (1981-1989), responsi ble for the vetting of proposed transactions by public companies. Then he mo ved to Evolution Securities (1989-2003) as head of Life sciences and progres sing as a joint head of Corporate Finance.
He has ser ved a number of companies as non-executive director or as director and among them as Chairman of Oxford Biomedica plc (2004-2016), Ipso Ventures plc (20 05-2013), Morvus technology  Ltd (2004-2012) and Spice Holdings plc (20 04-2006).